Valeant Pharmaceuticals Intl Inc.: The Good News and the Bad News

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in the midst of a very big week.

| More on:
The Motley Fool

Earlier this week I said that this will be a make-or-break week for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). The drug maker is hosting its investor day on Wednesday, and investors are looking for more clarity on how the company will move on from its recent controversies.

The week is still far from over; as of this writing, the investor day is still ongoing. But we can already report some big positives as well as some negatives from this week.

The positives: moving on from Philidor

Valeant’s shares surged on Tuesday when it announced a new 20-year distribution agreement with Walgreens Boots Alliance Inc. (NASDAQ:WBA). Under the agreement, Walgreens will sell Valeant’s signature skin and eye drugs at discounted prices and will sell 30+ other Valeant-branded drugs. Walgreens will also implement Valeant’s infamous copay assistance programs, in which insured patients can get their copays greatly reduced or waived altogether.

Of course, this arrangement means Valeant will have to sacrifice margins. But the company plans to make up the difference with increased volume.

On Wednesday, we got a greater idea of what this means for the company. Valeant is expecting profits to grow by 30% in 2016, which is well ahead of what analysts were expecting. Its stock rose in response. If you believe the company’s management, the whole controversy surrounding Philidor is behind it.

The negatives: something else is going on here

The news wasn’t all good. Valeant significantly lowered its fourth-quarter projections. The company now expects revenue of US$2.75 billion for the quarter, down from the earlier estimate of US$3.35 billion.

Everyone expected Valeant to revise its fourth-quarter projections, because the split with Philidor means lost revenue. However, Valeant lowered fourth-quarter revenue by an additional US$200 million due to “pricing and volume-related changes.” As a result, the company is expecting full-year profit of only US$10.23-10.33 per share. Analysts had been expecting a number above US$11.

If this is just a small blip, then of course it’s immaterial. After all, we’re talking about a difference of less than US$1 for a stock that now trades well above US$100.

But as the saying goes, “where there’s smoke, there’s fire.” In other words, Valeant’s revenue reductions could be a sign of greater problems to come. It could be a sign that insurers and pharmacy benefit managers are catching on to Valeant’s various practices and are fighting back. Only time will tell.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Express Scripts and Valeant Pharmaceuticals.

More on Investing

stock research, analyze data
Dividend Stocks

How Much to Invest to Get $500 in Dividends Every Month

TSX dividend stocks such as Enbridge, TD Bank, and Telus, can help you earn $500 in monthly dividend payments.

Read more »

A solar cell panel generates power in a country mountain landscape.
Energy Stocks

Clean Energy Play: Is Brookfield Renewable a Good Stock for a TFSA?

Add this top renewable energy stock to your self-directed TFSA portfolio for significant long-term and tax-free wealth growth.

Read more »

Golden crown on a red velvet background
Dividend Stocks

Dividend Powerhouses: Canadian Stocks to Fuel Your Portfolio

These two top Canadian dividend aristocrats are some of the top stocks on the TSX to buy now and hold…

Read more »

Dial moving from 4G to 5G
Dividend Stocks

This Undervalued Dividend Stock is Worth Buying Right Now

Want an undervalued dividend stock with long-term potential and a juicy yield? Here's an option you may regret not buying…

Read more »

A worker gives a business presentation.
Dividend Stocks

1 Stock I’m Buying Hand Over Fist in July Despite the Market’s Pessimism

This top dividend stock is going through a rough patch, but don't let that count out all the growth we've…

Read more »

financial freedom sign

2 Stocks With Millionaire-Maker Potential

These two top Canadian stocks are among the best on the TSX, and each has the potential to be millionaire-maker…

Read more »

Piggy bank next to a financial report
Stocks for Beginners

Is It Finally the Right Time to Buy Bank Stocks?

Canadian bank stocks are some of the most secure investments out there, but of them all, this bank stock is…

Read more »

clock time

3 Blue-Chip Stocks Every Canadian Should Own

Want some reliable blue-chip Canadian stocks to buy and hold for the next 10 years? These three stocks are worth…

Read more »